Thrombosis Journal最新文献

{"title":"Causal relationship between atherosclerosis and inflammatory bowel disease risk: a two-sample Mendelian randomization study.","authors":"Wenjuan Guo, Na Peng, Shiyu Du","doi":"10.1186/s12959-025-00722-y","DOIUrl":"https://doi.org/10.1186/s12959-025-00722-y","url":null,"abstract":"<p><strong>Objective: </strong>This study was to evaluate the causal associations of atherosclerosis with the risk of inflammatory bowel disease (IBD), and its subtypes [ulcerative colitis (UC) and Crohn's disease (CD)]: a two-sample Mendelian randomization study.</p><p><strong>Materials and methods: </strong>Single nucleotide polymorphism (SNPs) associated with atherosclerosis including CPAmax, CPSmax, brachial-femoral pulse wave velocity (bfPWV), coronary atherosclerosis, cerebral atherosclerosis, peripheral atherosclerosis, coronary artery disease (CAD) and ischemic stroke (IS) were identified from previous genome-wide association studies (GWAS). SNPs were strictly selected to fulfill the MR assumptions. The causal links between atherosclerosis and IBD were evaluated using inverse-variance weighted (IVW) as the primary method. Leave-one-out analysis was utilized to evaluate whether the outcomes were attributable to any individual SNP correlated to sex hormones. The estimates were subjected to odds ratio (OR) and 95% confidence interval (CI).</p><p><strong>Results: </strong>The results of IVW revealed that coronary atherosclerosis had causal association with increased risk of CD (OR = 1.162, 95%CI: 1.031-1.311). The causal association was also observed in IS with CD (OR = 1.376, 95%CI: 1.011-1.873) and UC (OR = 1.508, 95%CI: 1.153-1.971). Leave-one-out analysis indicated that no single SNP can affect the associations of CAD with IBD, CD, and UC, coronary atherosclerosis with CD, as well as IC with CD and UC.</p><p><strong>Conclusions: </strong>Coronary atherosclerosis was causally related to CD, and IS had causal relationship with CD and UC. The finding might provide evidence for future exploration of the etiology for IBD.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"39"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulopathy as a predictor of the effectiveness of tranexamic acid in severe blunt trauma: a multicenter retrospective study.","authors":"Yuki Takahashi, Mineji Hayakawa, Yuki Itagaki, Kota Ono, Daisuke Kudo, Shigeki Kushimoto","doi":"10.1186/s12959-025-00723-x","DOIUrl":"https://doi.org/10.1186/s12959-025-00723-x","url":null,"abstract":"<p><strong>Background: </strong>Tranexamic acid (TXA) reduces mortality in severe trauma cases. However, the relationships between TXA administration and coagulation/fibrinolysis abnormalities are unclear. We performed a retrospective observational study to investigate relationships between mortality and coagulation/fibrinolysis abnormalities of patients on arrival at the emergency department and whether TXA is more effective in patients with severe trauma who have coagulation/fibrinolysis abnormalities than in those who do not.</p><p><strong>Methods: </strong>Data was collected from 15 tertiary emergency and critical care centers in Japan. Adult patients with blunt trauma and an Injury Severity Score of ≥ 16 were included in the study. Patients were categorized into two groups: the TXA group received TXA within 3 h of arrival, and the non-TXA group did not.</p><p><strong>Results: </strong>Overall, 790 patients were included (TXA group, 276; non-TXA group, 514). In cubic spline curves for relationships between mortality and coagulation/fibrinolysis variables on arrival, odds for mortality increased and plateaued with a prothrombin time-international normalized ratio ≥ 1.2; the disseminated intravascular coagulation (DIC) score showed a marked odds increase when > 4 points. Odds increased and plateaued from an activated partial thromboplastin time (APTT) of ≥ 35 s and gradually increased as fibrinogen decreased from 250 mg/dL. Fibrinogen and fibrin degradation products (FDP) and D-dimer exhibited upward-sloping curves. In cubic spline curves for relationships between the effectiveness of TXA administration and coagulation/fibrinolysis variables on arrival, a favorable effect on mortality was observed with TXA administration when fibrinogen was ≤ 200 mg/dL or when the DIC score was ≥ 4 points; FDP, ≥ 50 µg/mL; D-dimer, ≥ 30 µg/mL; or APTT, ≥ 35 s. In each threshold subgroup, interactions between TXA administration and in-hospital mortality were observed.</p><p><strong>Conclusions: </strong>TXA demonstrates increased effectiveness in patients with traumatic coagulation/fibrinolysis abnormalities.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"37"},"PeriodicalIF":2.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel vs. ticagrelor in ST-elevation myocardial infarction complicated by cardiogenic shock undergoing primary PCI : Findings from a National, multicenter registry.","authors":"Can Zhou, Minghui Zhang, Zixu Zhao, Enze Li, Yichen Zhao, Wei Luo, Keyang Zheng, Yu Liu, Chengqian Yin, Xinyong Zhang, Hai Gao, Dong Zhao, Changsheng Ma","doi":"10.1186/s12959-025-00721-z","DOIUrl":"https://doi.org/10.1186/s12959-025-00721-z","url":null,"abstract":"<p><strong>Background: </strong>Although ticagrelor is recommended as opposed to clopidogrel in antiplatelet strategy for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI), evidence is limited in patients with cardiogenic shock (CS).</p><p><strong>Objective: </strong>This study aims to evaluate the comparative efficacy and safety profile of ticagrelor and clopidogrel in patients with STEMI-CS undergoing pPCI.</p><p><strong>Methods: </strong>Using data from a nationwide, multicenter registry, eligible patients were stratified into clopidogrel or ticagrelor based on the choice of P2Y₁₂ inhibitors within 24 h of first medical contact. Multivariable-adjusted Cox regression analyses, along with Cox models adjusted for propensity score matching and inverse probability treatment weighting were conducted to compare outcomes between ticagrelor and clopidogrel. The efficacy and safety outcomes were in-hospital all-cause mortality and major bleeding.</p><p><strong>Results: </strong>Among 729 STEMI-CS patients in our cohort, 403 received clopidogrel and 326 received ticagrelor. Multivariable-adjusted Cox regression analyses showed that ticagrelor was not associated with a significant difference in all-cause mortality (adjusted HR: 1.04; 95% CI: 0.69-1.56; p = 0.840) and major bleeding (adjusted HR: 1.30; 95% CI: 0.62-2.76; p = 0.489) compared to clopidogrel. Consistent results were found in the analyses adjusted by propensity score matching and inverse probability of treatment weighting.</p><p><strong>Conclusions: </strong>Our findings suggest that the choice of either ticagrelor or clopidogrel was feasible as a P2Y₁₂ inhibitor for dual anti-platelet strategy in STEMI-CS patients undergoing pPCI, as no significant difference between these two agents was observed in all-cause mortality and major bleeding during hospitalization.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT02306616. Registered 29 November 2014.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"38"},"PeriodicalIF":2.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-associated venous thromboembolism: a comprehensive review.","authors":"Tingting Wan, Jia Song, Dapeng Zhu","doi":"10.1186/s12959-025-00719-7","DOIUrl":"https://doi.org/10.1186/s12959-025-00719-7","url":null,"abstract":"<p><p>It has been 200 years since the first case of cancer-associated thrombosis (CAT) was reported. Venous thromboembolism (VTE) remains a leading cause of morbidity and mortality in cancer patients. Malignant tumors interact with the coagulation system in complex ways. CAT continues to pose a significant challenge in clinical practice. The risk factors for CAT are complex and multifactorial, primarily including patient, cancer, and therapy-related factors. We have introduced assessment models for CAT and bleeding risk, but the performance of these models has been less than satisfactory. Currently, the main anticoagulant drugs for treating CAT include vitamin K antagonists (VKAs), low molecular weight heparin (LMWH), and direct oral anticoagulants (DOACs). We have provided a detailed overview of the advantages and disadvantages of these three types of drugs and suggestions on choosing the appropriate type of medication for different clinical scenarios. CAT incidence, pathophysiology, risk factors, risk prediction models, and recent advancements in treatment and management are summarized in this review.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"35"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The proportion of young male hemophilia patients who underwent ultrasound examinations: an observational study using a nationwide claims database.","authors":"Yosuke Uchihashi, Tatsuya Noda, Yusuke Inagaki, Kenichi Ogiwara, Yuya Mawarikado, Yuichi Nishioka, Tomoya Myojin, Kagehiro Amano, Akira Shirahata, Keiji Nogami, Akira Kido, Tomoaki Imamura","doi":"10.1186/s12959-025-00724-w","DOIUrl":"https://doi.org/10.1186/s12959-025-00724-w","url":null,"abstract":"<p><strong>Background: </strong>Advances in hemophilia treatment have reduced bleeding episodes in patients with hemophilia (PWH) and improved their musculoskeletal prognosis; however, complete prevention of musculoskeletal disorders has not been achieved. Recently, the usefulness of ultrasound (US) examinations in the musculoskeletal assessment of PWH has been reported, but the actual use of US has been suggested to be limited. The aim of this study was to clarify the extent to which US is being performed on young male PWH at medical institutions in Japan.</p><p><strong>Methods: </strong>This was an observational study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We identified almost all male PWH aged under 30 years who were prescribed hemostatic agents between 2015 and 2021 in Japan. For each year, we calculated the proportion of PWH who underwent US and, as a sensitivity analysis, the proportion of PWH who underwent US examinations for musculoskeletal disease. The Cochran‒Armitage trend test was used to examine changes in the number of PWH who underwent US examinations over the observation period. The Lorenz curves and Gini coefficients were calculated from the proportion of US examinations performed at each medical institution annually.</p><p><strong>Results: </strong>A total of 2137-2483 male PWH younger than 30 years were identified annually. The annual proportion of PWH who underwent US ranged from 6.1 to 12.9%. By age group, the annual proportions of US were 6.7-14.4%, 8.1-16.6%, and 2.0-8.7% for 0-9, 10-19, and 20-29 years, respectively. The annual proportions of musculoskeletal US were 2.9-7.7%. The proportion of PWH who underwent US increased significantly over the seven-year period; however, it varied by medical institution (Gini coefficients 0.85-0.92).</p><p><strong>Conclusions: </strong>The use of US for young PWH is becoming more widespread in Japan. However, US is performed at different rates among medical institutions.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"34"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism.","authors":"Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa","doi":"10.1186/s12959-025-00720-0","DOIUrl":"https://doi.org/10.1186/s12959-025-00720-0","url":null,"abstract":"<p><strong>Background: </strong>Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence. In patients with cancer, however, recurrent VTE after DOAC treatment may be more common than in noncancer patients. To evaluate our hypothesis that the anticoagulation effect of edoxaban is lower in VTE patients with cancer than in noncancer patients.</p><p><strong>Methods: </strong>This study was a prospective, multicenter, observational study including patients treated with edoxaban for VTE in Japan. The primary outcome was the difference in the prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer level at 5 h after initial edoxaban administration between the cancer and noncancer groups. An additional outcome was the longitudinal change in PT and APTT from 5 h to overnight after edoxaban administration. The incidence of adverse events was further investigated.</p><p><strong>Results: </strong>PT and APTT at 5 h after initial edoxaban administration were not significantly different between the cancer (n = 84) and noncancer groups (n = 138) (e.g., log-transformed APTT 3.55 vs. 3.55, p = 0.45). However, D-dimer in the cancer groups was significantly greater than that in the noncancer groups (log-transformed 1.83 vs. 1.79, p = 0.009). PT and APTT significantly decreased from 5 h to overnight after edoxaban, but a similar pattern was observed in each group. All adverse events after edoxaban administration were also similar between patients with cancer and noncancer.</p><p><strong>Conclusion: </strong>PT and APTT after edoxaban administration were similar between VTE patients with cancer and noncancer groups, suggesting that edoxaban has anticoagulation effects on cancer-associated VTE similar to those of noncancer patients.</p><p><strong>Trial registration: </strong>UMIN000041973; Registration Date: 2020.10.5.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"36"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer.","authors":"Sheng-Chieh Chou, Shu-Lun Chang, Cheng-Yeh Yu, Chao-I Lin, Yen-Ting Chang, Li-Fu Chen, Jia-Yi Li, Chen-Hsueh Pai, Shu-Rung Lin, Wern-Cherng Cheng, Chang-Tsu Yuan, Shu-Wha Lin","doi":"10.1186/s12959-025-00715-x","DOIUrl":"https://doi.org/10.1186/s12959-025-00715-x","url":null,"abstract":"<p><strong>Background: </strong>Tissue factor (TF)-rich cancer microvesicles are correlated with thrombosis risk. Intrinsic coagulation factors are also associated with the risk of thrombosis in cancer patients. This study explored the roles of pancreatic cancer-derived microvesicles and intrinsic factors in thrombogenesis.</p><p><strong>Methods: </strong>Human pancreatic cancer cell lines rich in TF (AsPC-1-TF^high, MIAPaCa-2-TF^high) or poor in TF [AsPC-1-TF^KO(knockout) and MIAPaCa-2-TF^low] were generated for microvesicle preparation and injected into coagulation-defective mice. Inferior vena cava (IVC) clots and lung thrombosis were evaluated. Immunodeficient hemophilia A (NSG-HA) mice were orthotopically injected with the cells mentioned above, and the tumor and IVC clot weights were analyzed.</p><p><strong>Results: </strong>With the injection of TF^high microvesicles, IVC clots were rarely found in hemophilic mice. The TF^low and TF^KO microvesicles resulted in few IVC clots in any mouse. Lung thrombosis was substantially reduced in the hemophilic mice infused with any microvesicle type. In orthotopic tumor models, TF^high cells grew faster than did TF^low cells. TF^high tumor-bearing NSG-WT mice had the most enormous IVC clots, whereas NSG-HA mice had no IVC clots.</p><p><strong>Conclusion: </strong>Pancreatic cancer thrombosis induced by TF-expressing microvesicles strongly depended on FVIII and FIX, while VWF played a minor role. Moreover, TF, but not FVIII, was significantly related to tumor growth.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"32"},"PeriodicalIF":2.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the risk of postoperative venous thromboembolism in rhinoplasty patients: a cohort study.","authors":"Jie Chen, Jianfei Zhang, Xia Xiao, Yujun Tang, Hejin Huang, Wenwen Xi, Lina Liu, Zhengzhou Shen, Jianhua Tan, Feng Yang","doi":"10.1186/s12959-025-00712-0","DOIUrl":"https://doi.org/10.1186/s12959-025-00712-0","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a rare complication following rhinoplasty surgery, with an occurrence rate generally estimated to be between 0.5% and 1%. In contrast, the occurrence rate of VTE in orthopedic surgeries, particularly in lower limb fracture surgeries, can reach as high as 10% or more. This significant difference highlights the varying risks associated with different surgical procedures and underscores the importance of identifying risk factors specific to rhinoplasty. Despite its relatively low incidence, the potential for VTE in rhinoplasty patients necessitates a thorough analysis of risk factors to enhance patient safety and guide clinical practice. This study aims to analyze the risk factors for postoperative VTE in rhinoplasty patients and develop a predictive model to assist clinicians in identifying at-risk individuals.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 1100 rhinoplasty patients admitted to a cosmetic hospital from January 2016 to January 2022. Patients were divided into Non-VTE group (1012 cases) and VTE group (88 cases) based on the occurrence of VTE within one month postoperatively. General patient information was collected and subjected to univariate analysis. Multivariate logistic regression analysis was used to identify risk factors for postoperative VTE in rhinoplasty patients and establish a predictive model. Internal validation was performed using bootstrapping technique to assess the accuracy and predictive performance of the model.</p><p><strong>Results: </strong>Univariate analysis showed that the proportions of IBD, Myocardial infarction, Previous VTE, PICC/central line, Rib graft, and History of nasal surgery were significantly higher in the VTE group compared to the Non-VTE group (all P < 0.05). Multivariate logistic regression analysis identified IBD, Myocardial infarction, Previous VTE, Rib graft, and History of nasal surgery as independent risk factors for VTE (P < 0.05). The constructed predictive nomogram model demonstrated good calibration and predictive accuracy, with an area under the ROC curve of 0.845, indicating excellent discrimination and clinical predictive performance.</p><p><strong>Conclusion: </strong>IBD, Myocardial infarction, Previous VTE, Rib graft, and History of nasal surgery are independent risk factors for postoperative VTE in rhinoplasty patients. The predictive model effectively assesses the risk of VTE in patients, providing important guidance for clinical decision-making.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"33"},"PeriodicalIF":2.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboelastography-based dynamic evaluation of perioperative coagulation changes and anticoagulant efficacy in lung cancer patients.","authors":"Songping Cui, Ruiheng Jiang, Jiaojie Zhao, Jing Wang, Bin Hu, Hui Li, Shuo Chen","doi":"10.1186/s12959-025-00718-8","DOIUrl":"https://doi.org/10.1186/s12959-025-00718-8","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a common postoperative complication in oncologic surgery, closely associated with perioperative hypercoagulability. Thromboelastography (TEG) may be an effective method for monitoring hypercoagulability and guiding preventive anticoagulation.</p><p><strong>Methods: </strong>We prospectively collected perioperative clinical data from lung cancer surgery patients at our hospital between June 2019 and January 2020. TEG and coagulation-related indicators were monitored preoperatively, and on postoperative days 1 and 3. Newly diagnosed postoperative VTE was monitored using lower limb color doppler ultrasound.</p><p><strong>Results: </strong>A total of 241 lung cancer surgery patients were included, with 25 developing VTE postoperatively (10.4%). TEG results showed a significant decrease in the R value (a thrombin marker) on postoperative day 1, followed by an increase on day 3. The MA value (a platelet marker) increased postoperatively. D-dimer levels also rose after surgery. On postoperative day 1, thrombin-related hypercoagulability was predominant (15/17 preoperatively, 40/46 postoperatively), whereas platelet-related hypercoagulability was dominant on postoperative day 3 (18/35). Patients who received prophylactic anticoagulation had significantly higher R values on day 3. The ROC curve for D-dimer predicting new-onset VTE showed AUCs of 0.732, 0.790, and 0.847 preoperatively, on days 1, and 3, respectively.</p><p><strong>Conclusion: </strong>D-dimer helps identify high-risk patients for postoperative VTE, while TEG aids in classifying and monitoring hypercoagulability, optimizing anticoagulation therapy choices and dosages.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"31"},"PeriodicalIF":2.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of combined oral contraceptives on thrombin generation assessed on ST Genesia- a paired clinical study.","authors":"Jesper Strandberg, Inger Lise Gade, Jette Nybo, Janus Nikolaj Laust Thomsen, Søren Risom Kristensen","doi":"10.1186/s12959-025-00713-z","DOIUrl":"10.1186/s12959-025-00713-z","url":null,"abstract":"<p><strong>Background: </strong>Treatment with combined oral contraceptives (COC) is associated with an increased risk of venous thromboembolism. Several changes of coagulant and anticoagulant factors induced by ethinyloestradiol during treatment with COC, have been demonstrated. Thrombin generation is a global test measuring both coagulant and anticoagulant factors, but the effect of COC on individuals starting COC, has not been examined before on the new equipment, ST Genesia. The aim of this project was to examine the effect of COC on thrombin generation on ST Genesia, in individuals before and after starting COC.</p><p><strong>Methods: </strong>Twenty-four female participants between 15 and 34 years of age, who were about to start treatment with ethinylestradiol/levonorgestrel-containing COC, were included in the study. Two blood samples were drawn from each of the study subjects, a baseline sample immediately before first COC dose, and a follow-up blood sample approximately 3-4 months after COC start. Standard biochemical analyses as well as standard and special coagulation analyses including thrombin generation on ST Genesia, were performed in all samples.</p><p><strong>Results: </strong>Thrombin generation, i.e., endogenous thrombin generation (ETP) and peak increased considerably after COC start, whereas time-to-peak was shortened. Thrombin-antithrombin complexes (TAT), prothrombin fragments (F1 + 2) and sex hormone binding globulin (SHBG) increased, and the coagulation inhibitors tissue factor pathway inhibitor (TFPI), protein S activity and antithrombin decreased slightly after COC start.</p><p><strong>Conclusion: </strong>Although the coagulation factors only changed modestly, the global test thrombin generation performed on ST Genesia showed a considerable change after start of COC.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"30"},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}